Everolimus pharmacokinetics in fed versus fasting volunteers

Trial Profile

Everolimus pharmacokinetics in fed versus fasting volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2011

At a glance

  • Drugs Everolimus (Primary)
  • Indications Astrocytoma; Breast cancer; Coronary artery restenosis; Diffuse large B cell lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Heart transplant rejection; Liver cancer; Liver transplant rejection; Lung transplant rejection; Neuroendocrine tumours; Pancreatic cancer; Renal cancer; Renal cell carcinoma; Renal transplant rejection; Urogenital cancer
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 27 Jun 2011 New trial record
    • 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top